RET (L730I)
Sign in to save this workspaceRET · Variant type: point · HGVS: p.L730I
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Fedratinib | 99.4% | 0.6% | 96.21 |
| 2 | Pralsetinib | 98.1% | 1.9% | 93.43 |
| 3 | Selpercatinib | 97.8% | 2.2% | 96.72 |
| 4 | Tivozanib | 97.0% | 3.0% | 92.42 |
| 5 | Erdafitinib | 84.9% | 15.1% | 95.71 |
| 6 | Sorafenib | 84.8% | 15.2% | 96.72 |
| 7 | Repotrectinib | 84.3% | 15.7% | 84.21 |
| 8 | Vandetanib | 81.4% | 18.6% | 95.74 |
| 9 | Ripretinib | 77.2% | 22.9% | 92.95 |
| 10 | Apatinib | 75.5% | 24.5% | 97.73 |
| 11 | Gilteritinib | 69.2% | 30.8% | 88.97 |
| 12 | Sunitinib | 64.9% | 35.1% | 91.73 |
| 13 | Entrectinib | 64.8% | 35.2% | 93.69 |
| 14 | Alpelisib | 64.7% | 35.3% | 97.22 |
| 15 | Avapritinib | 62.6% | 37.4% | 97.73 |
| 16 | Tenalisib | 62.4% | 37.6% | 97.98 |
| 17 | Canertinib | 55.3% | 44.7% | 96.49 |
| 18 | Defactinib | 39.8% | 60.2% | 92.68 |
| 19 | Quizartinib | 36.0% | 64.0% | 99.50 |
| 20 | Futibatinib | 24.4% | 75.6% | 98.48 |
| 21 | Pemigatinib | 21.7% | 78.3% | 98.23 |
| 22 | Pexidartinib | 19.2% | 80.8% | 99.49 |
| 23 | Upadacitinib | 16.3% | 83.7% | 97.98 |
| 24 | Deucravacitinib | 13.9% | 86.1% | 98.99 |
| 25 | Erlotinib | 12.9% | 87.1% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Fedratinib | 99.4% | 99.9% | -0.4% |
| Pralsetinib | 98.1% | 100.0% | -1.9% |
| Selpercatinib | 97.8% | 100.0% | -2.2% |
| Tivozanib | 97.0% | 99.7% | -2.8% |
| Erdafitinib | 84.9% | 94.7% | -9.7% |
| Sorafenib | 84.8% | 94.0% | -9.1% |
| Repotrectinib | 84.3% | — | — |
| Vandetanib | 81.4% | 98.6% | -17.2% |
| Ripretinib | 77.2% | — | — |
| Apatinib | 75.5% | — | — |
| Gilteritinib | 69.2% | 100.0% | -30.8% |
| Sunitinib | 64.9% | 97.2% | -32.4% |
| Entrectinib | 64.8% | 99.6% | -34.8% |
| Alpelisib | 64.7% | 99.6% | -34.9% |
| Avapritinib | 62.6% | — | — |
| Tenalisib | 62.4% | 98.5% | -36.1% |
| Canertinib | 55.3% | — | — |
| Defactinib | 39.8% | — | — |
| Quizartinib | 36.0% | — | — |
| Futibatinib | 24.4% | 97.7% | -73.3% |
| Pemigatinib | 21.7% | — | — |
| Pexidartinib | 19.2% | — | — |
| Upadacitinib | 16.3% | — | — |
| Deucravacitinib | 13.9% | — | — |
| Erlotinib | 12.9% | — | — |
Cancer associations
| Cancer | Organ | Source |
|---|---|---|
| carcinoma_thyroid | Thyroid | ref |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 13.0ms